Brief: Sequana Medical Updates On Results From Second Interim Analysis Of North American Pivotal Alfapump Study

Sequana Medical NV

01/07/2021 06:04

July 1 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES POSITIVE RESULTS FROM SECOND INTERIM ANALYSIS OF
NORTH
AMERICAN PIVOTAL ALFAPUMP® STUDY (POSEIDON)
    * INTERIM DATA FROM 26 PATIENTS IN ROLL-IN COHORT RECONFIRM POSITIVE
OUTCOMES
AGAINST ALL PRIMARY ENDPOINTS
    * OVER 90% REDUCTION IN MEAN FREQUENCY OF THERAPEUTIC PARACENTESIS VERSUS
BASELINE
    * PRIMARY ENDPOINT DATA OF PIVOTAL COHORT EXPECTED IN Q3 2022
    * COMPLETION OF PATIENT ENROLMENT IS NOW EXPECTED IN Q3 2021 INSTEAD OF Q2
2021,
WITH PLANNED REPORTING OF PRIMARY ENDPOINT IN Q3 2022
    * SAFETY PROFILE REMAINS IN LINE WITH EXPECTATIONS - THREE PATIENTS
EXPERIENCED A
COMPOSITE PRIMARY SAFETY EVENT

Source text for Eikon:  ID:nGNE4Vkl6S 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))